Ofatumumab: A new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 5, 2010, Pages 361-368

  O'Brien, Susan ^a   Österborg, Anders ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Complement dependent cytotoxicity; Fludarabine refractory; Rituximab resistance

Indexed keywords

ALEMTUZUMAB; CD20 ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; EPITOPE; FLUDARABINE; OFATUMUMAB; PENTOSTATIN; RITUXIMAB; CD20 ANTIGEN; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DEATH; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; INJECTION SITE REACTION; LARGE CELL LYMPHOMA; LYMPHADENOPATHY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 79952278698     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.069     Document Type: Review

References (88)

1. Robak T. Recent progress in the management of chronic lymphocytic leukemia. Cancer Treat Rev 2007; 33:710-28. (Pubitemid 350089291)
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. Ca Cancer J Clin 2010; 60:277-300.
3. Binet JL, Lepoprier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977; 40:855-64. (Pubitemid 8177910)
4. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46:219-34.
5. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87:4990-7. (Pubitemid 26189840)
6. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446-56.
7. Zenz T, Mertens D, Dohner H, et al. Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications. Leuk Lymphoma 2008; 49:864-73. (Pubitemid 351942738)
8. Higgins RA, Gunn SR, Robetorye RS. Clinical application of array-based comparative genomic hybridization for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia. Mol Diagn Ther 2008; 12:271-80.
9. Tam CS, Otero-Palacios J, Abruzzo LV, et al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol 2008; 141:36-40. (Pubitemid 351347535)
10. National Cancer Institute. US National Cancer Institutes. Chronic lymphocytic leukemia treatment (PDQ®). Available at: http://www.cancer.gov/ cancertopics/pdq/treatment/CLL/Patient/page5. Accessed: August 8, 2008.
11. TREANDA prescribing information. 2008. Available at: http://www.treanda. com/?s-kwcid=bendamustine|2320350978. Accessed: August 7, 2008.
12. Hamblin TJ. Achieving optimal outcomes in chronic lymphocytic leukaemia. Drugs 2001; 61:593-611. (Pubitemid 32453371)
13. Knauf W, Lissichkov T, Aldaoud A, et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an international Phase III study. Blood 2007; 110: (abstract 2043).
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas V.2. Available at: http://www.nccn.org/ professionals/default.asp. Accessed: August 8, 2008.
15. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27:4378-84.
16. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107:885-91. (Pubitemid 43156283)
17. Schmitt B, Wendtner CM, Bergmann M, et al. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin Lymphoma 2002; 3:26-35.
18. Brugiatelli M, Bandini G, Barosi G, et al. Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2006; 91:1662-73. (Pubitemid 46032963)
19. Lin TS. What is the optimal initial treatment for chronic lymphocytic leukemia? Oncology (Williston Park) 2007; 21:1641-9; discussion 9-54, 59, 62.
20. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19:2153-64. (Pubitemid 32366969)
21. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23:4079-88. (Pubitemid 46211313)
22. Anderson J, Cain K, Gelber R. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 2008; 26:3913-5.
23. Cao TM, Coutre SE. Management of advanced chronic lymphocytic leukemia. Curr Hematol Rep 2003; 2:65-72.
24. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43:1755-62. (Pubitemid 34874007)
25. Tam CS, O'Brien S, Lerner S, et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 2007; 48:1931-9. (Pubitemid 47542979)
26. Perkins JG, Flynn JM, Howard RS, et al. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002; 94:2033-9. (Pubitemid 34270057)
27. National Cancer Institute. Surveillance epidemiology and end results. SEER stat fact sheets - chronic lymphocytic leukemia. Available at: http://seer.cancer.gov/statfacts/html/clyl.html. Accessed: June 23, 2009.
28. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25:5616-23.
29. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20:3891-7.
30. Grever MR, Lucas DM, Johnson AJ, et al. Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007; 20:545-56. (Pubitemid 47250499)
31. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910-6. (Pubitemid 32064784)
32. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25:799-804. (Pubitemid 350010635)
33. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370:230-9. (Pubitemid 47069536)
34. Osterborg A, Karlsson C, Lundin J, et al. Strategies in the management of alemtuzumab-related side effects. Semin Oncol 2006; 33:S29-35.
35. Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recomendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006; 132:3-12. (Pubitemid 43381565)
36. Osterborg A, Foa R, Bezares RF, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009; 23:1980-8.
37. Cragg MS, Walshe CA, Ivanov AO, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140-74.
38. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15:450-4. (Pubitemid 24272191)
39. Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44:3823-37. (Pubitemid 47332625)
40. Einfeld DA, Brown JP, Valentine MA, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988; 7:711-7.
41. Liu AY, Robinson RR, Murray ED, Jr, et al. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 1987; 139:3521-6. (Pubitemid 18022010)
42. Sieber T, Schoeler D, Ringel F, et al. Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells. Br J Haematol 2003; 121:458-61. (Pubitemid 36628337)
43. Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003; 101:2507-13. (Pubitemid 36857605)
44. Williams ME, Densmore JJ, Pawluczkowycz AW, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006; 177:7435-43. (Pubitemid 44715114)
45. Giles FJ, Vose JM, Do KA, et al. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol 2003; 123:850-7. (Pubitemid 37533297)
46. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12:177-86. (Pubitemid 27349961)
47. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101:949-54. (Pubitemid 36139365)
48. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51:634-41. (Pubitemid 30353375)
49. Beers SA, Chan CHT, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008; 112:4170-7.
50. D'Arena G, Musto P, Cascavilla N, et al. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol 2000; 64:275-81. (Pubitemid 30622235)
51. Rossmann ED, Lenkei R, Lundin J, et al. Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2007; 72:450-7. (Pubitemid 350086251)
52. Martin P, Furman RR, Ruan J, et al. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Semin Hematol 2008; 45:126-32. (Pubitemid 351444841)
53. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005; 23:1103-8. (Pubitemid 46202265)
54. Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17:1851-7. (Pubitemid 29269257)
55. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92:1927-32. (Pubitemid 28446681)
56. Feuring-Buske M, Kneba M, Unterhalt M, et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000; 79:493-500.
57. Hainsworth JD, Litchy S, Burris HA, 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002; 20:4261-7. (Pubitemid 35191030)
58. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98:1326-31.
59. Itala M, Geisler CH, Kimby E, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 2002; 69:129-34. (Pubitemid 35335149)
60. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94:2217-24. (Pubitemid 29467667)
61. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21:1746-51. (Pubitemid 46638587)
62. Ghia P, Ferreri AM, Galigaris-Cappio F. Chronic lymphocytic leukemia. Crit Rev Oncol Hematol 2007; 64:234-46. (Pubitemid 350026781)
63. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100:768-73. (Pubitemid 34832599)
64. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19:2165-70. (Pubitemid 32366970)
65. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101:6-14. (Pubitemid 36025880)
66. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105:49-53. (Pubitemid 40053062)
67. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23:4070-8. (Pubitemid 46211312)
68. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006; 24:1575-81. (Pubitemid 46638781)
69. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007; 109:405-11. (Pubitemid 46105933)
70. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101:3413-5. (Pubitemid 36857922)
71. Nabhan C, Patton D, Gordon LI, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004; 45:2269-73. (Pubitemid 39504321)
72. Frankfurt O, Ma S, Hamilton E, et al. Long term results of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for patients with relapsed and refractory chronic lymphocytic leukemia. Haematologica 2009; 94(suppl 3):9.8.
73. Hallek M, Fingerle-Rowson G, Fink A-M, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 2008; 112:325.
74. Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group. Blood 2009; 114:535.
75. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1756-65.
76. Badoux X, Keating MJ, O'Brien SM, et al. Long term results of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for patients with relapsed and refractory chronic lymphocytic leukemia. Haematologica 2009; 94(suppl 3):10.32.
77. O'Brien S, Wierda W, Faderl S, et al. FCR-3 as Frontline Therapy for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 2005; 106: (abstract 2117).
78. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177:362-71. (Pubitemid 43939148)
79. van Meerten T, van Rijn RS, Hol S, et al. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006; 12:4027-35. (Pubitemid 44078090)
80. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008; 14:1561-70. (Pubitemid 351413941)
81. Robak T. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Curr Cancer Drug Targets 2008; 8:156-71. (Pubitemid 351347252)
82. US National Institutes of Health. ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov/ct2/results?term=ofatumumab+. Accessed: June 17, 2009.
83. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104:1793-800. (Pubitemid 39202289)
84. Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008; 181:822-32.
85. Taylor R, Pawluczkowycz A, Lindorfer M, et al. Binding of submaximal C1q to B cells opsonized with anti-CD20 mabs ofatumumab (OFA) or rituximab (RTX) promotes complement dependent cytotoxicity (CDC), and considerably higher levels of CDC are induced by OFA than by RTX. Blood 2008; 112:560 (abstract 1578).
86. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111:1094-100. (Pubitemid 351213387)
87. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1749-55.
88. Wierda WG, Kipps TJ, Durig J, et al. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, Phase II trial. Blood 2009; 114: (abstract 207)